Refine by
Transformer Technology Articles & Analysis
90 news found
CD Genomics, a leading provider of genomic research solutions, today announced the launch of its cutting-edge Nanopore sequencing services, marking a significant advancement in DNA and RNA analysis capabilities. This innovative technology, developed by Oxford Nanopore Technologies, is set to transform the landscape of life sciences research, ...
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary ...
Alfa Chemistry's new line of SMAs offers exceptional performance and reliability, making them the top choice for engineers looking to push the boundaries of what is possible with materials technology. Nitinol SMAs, in particular, are a specific type of shape memory alloy composed of nickel and titanium. ...
Betting on healthcare as a key market, Avant Technologies, Inc. (OTCQB: AVAI) just announced the completion of its acquisition of privately-held healthcare technology and data integration services firm, Wired-4-Health. ...
This appointment underscores Synaptive’s commitment to driving sales, expanding its market presence, and advancing innovative solutions in imaging and surgical technology focused on combining the best technologies with the best information to transform the delivery of care. ...
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). ...
“Additionally, this partnership will provide important insights about the impact of innovative technology and advanced healthcare solutions on real-world patient ...
CD Genomics, a prominent leader in the genomics and transcriptomics arena, proudly unveils its latest innovation, the Degradome Sequencing service. This technology promises to revolutionize the field of transcriptomics research, offering researchers an unprecedented window into RNA degradation patterns and elevating our comprehension of gene regulation and expression. ...
Tris developed both formulations using the company’s proprietary LiquiXR® technology. “Quillivant ER has the potential to address a significant unmet market need in the treatment of ADHD by overcoming drawbacks associated with many other ADHD medications, particularly among children,” said John McKendry, president at KYE Pharmaceuticals. ...
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. ...
About Tris Pharma Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. ...
“Tris has a proven track record of applying its drug development capabilities and proprietary technologies globally to develop, manufacture and commercialize medicines that improve upon traditional therapies,” said Dr. ...
Breukelman is a pioneer in imaging technology, initially as principal and chairman of IMAX Corporation, followed by significant transformative contributions to medical and scientific research companies in information technology and strategic development. ...
This acquisition of Cellesce affirms Molecular Devices’ commitment to investing in 3D biology technologies that transform the drug discovery process and drive development of novel therapeutics. ...
“It is a true honor to be joining Portal and having the opportunity to bring this innovative technology to market with such a highly talented and passionate team.”. About Portal Instruments Portal Instruments is developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the ...
“This partnership is another step forward in our efforts to leverage game-changing clinical technology to transform the care delivered in and outside of our hospitals and clinics,” said Ardent Chief Executive Officer Marty Bonick. ...
BRIM Biotechnology, Inc. was established in July 2013 to acceleratethe development and transformation of early research technology platforms to clinical drug candidates. ...
Key Takeaways: Next-generation single-molecule protein sequencing technology is poised to transform the science and research community’s understanding of the proteome by unlocking unprecedented insights about the human body - just as the advent of next-generation DNA sequencing has revolutionized our knowledge of the human genome over the past two ...
Anavasi Diagnostics ('Anavasi'), a medical technology company focused on the development of novel molecular diagnostic testing, recently announced the addition of a Chief Financial Officer, Chief Operating Officer and Chief Commercial Officer to its management roster. ...
Mammoth Biosciences, a biotech company harnessing next-generation CRISPR technology to detect and cure disease, has been chosen by Endpoints News Editor John Carroll as one of the most promising biotech startups for this year’s Endpoints 11 annual special report. ...